Date: July 25, 2024 By: Nick Kolev
The Ragon Institute is proud to recognize Upasana Das Adhikari, PhD, a postdoctoral fellow in the Kwon Lab, who has been awarded the prestigious K99 Pathway to Independence Award by the National Institutes of Health (NIH). This highly competitive award identifies trainees with strong potential to become independent scientists and supports them through this critical transition.
Das Adhikari joined the Kwon Lab as a postdoctoral fellow in July 2019. Before moving to Boston, she was a Signgene Fellow working on a collaborative project between the Hebrew University of Jerusalem and the Max Delbruck Centre of Molecular Medicine in Berlin. During her PhD, she studied gut epithelial stem cell regeneration, focusing on the crosstalk between reserve and active stem cells.
Her fascination with the interactions between the epithelium, gut associated lymphoid tissue, and the microbiome led her to the lab of Ragon faculty member Doug Kwon, MD. PhD, where she now investigates the imbalance of these interactions during HIV disease progression.
The NIH K99 Pathway to Independence Award provides Das Adhikari with up to two years of mentored support followed by up to three years of independent support. This award is designed to help postdoctoral researchers transition to academic positions, facilitating their development into independent researchers.
Das Adhikari’s award recognizes her exceptional potential and provides her with the resources to further her innovative research. This support will enable her to continue her critical work in understanding the interactions within the gut during HIV progression and contribute to the development of new strategies to combat HIV and other gut inflammatory diseases.
Congratulations, Dr. Adhikari!
Researchers at the Ragon Institute of Mass General Brigham, MIT, and Harvard have uncovered critical insights into how aging impairs the immune system’s ability to fight cancer.
This study, published in Immunity on August 30, used a non-human primate model to demonstrate that previous Mtb infection leads to a durable, protective immune response that is dependent on CD4+ T cells.
MIT researchers find that the first dose primes the immune system, helping it to generate a strong response to the second dose, a week later.